The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Transarterial chemoembolization (TACE) is considered the gold standard for treating
intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not
specify the criteria for repeating TACE. The study,conducted in Europe ，recently published in
the journal of Hepatology shows the ART score of >=2.5 prior the second TACE identifies
patients with a dismal prognosis who may not profit from further TACE sessions. However,in
clinical practice，we also found some patients who showed TACE-resistant at the beginning of
treatment may access to get objective response of retreatment with transcatheter arterial
infusion (TAI). So the investigators conduct this prospective,randomized controlled study to
find out whether the patient who showed TACE-resistant can obtain survival benefit from
retreatment with TAI.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Guangzhou No.12 People's Hospital Kaiping Central Hospital